Exercise protects against MPTP-induced neurotoxicity in mice.

Brain Research
Kimberly M GereckeRichard J Smeyne

Abstract

Exercise has been shown to be potently neuroprotective in several neurodegenerative models, including 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) model of Parkinson's disease (PD). In order to determine the critical duration of exercise necessary for DA neuroprotection, mice were allowed to run for either 1, 2 or 3months prior to treatment with saline or MPTP. Quantification of DA neurons in the SNpc show that mice allowed to run unrestricted for 1 or 2months lost significant numbers of neurons following MPTP administration as compared to saline treated mice; however, 3months of exercise provided complete protection against MPTP-induced neurotoxicity. To determine the critical intensity of exercise for DA neuroprotection, mice were restricted in their running to either 1/3 or 2/3 that of the full running group for 3months prior to treatment with saline or MPTP. Quantification of DA neurons in the SNpc show that mice whose running was restricted lost significant numbers of DA neurons due to MPTP toxicity; however, the 2/3 running group demonstrated partial protection. Neurochemical analyses of DA and its metabolites DOPAC and HVA show that exercise also functionally protects neurons from MPTP-induced neurotoxicity. Pr...Continue Reading

References

Jan 1, 1992·Clinical Neurology and Neurosurgery·O Hornykiewicz
Dec 1, 1992·Psychology and Aging·H L HawkinsD Capaldi
May 11, 1992·Annals of the New York Academy of Sciences·I J Kopin
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·P Jenner
Mar 1, 1990·Journal of Neurochemistry·A H SchapiraC D Marsden
Jan 1, 1989·Journal of Neural Transmission·W J BrooksG C Wagner
Oct 1, 1989·Annals of Neurology·D C GermanC B Saper
Jan 1, 1970·Annual Review of Biochemistry·C Villar-Palasi, J Larner
Jan 12, 1995·Nature·S A NeeperC Cotman
Jun 1, 1993·British Journal of Pharmacology·M Del ZompoA Vaccari
Sep 1, 1995·Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration·V Jackson-LewisS Przedborski
Dec 1, 1996·Neurology·S Fahn
Jan 1, 1997·Journal of Neuropathology and Experimental Neurology·M SandriU Carraro
May 8, 1998·Journal of Neurochemistry·R R GainetdinovM G Caron
Aug 28, 1998·International Journal of Sports Medicine·C Y GuezennecM Peres
Apr 15, 1999·Annual Review of Neuroscience·C W Olanow, W G Tatton
Sep 28, 1999·Trends in Pharmacological Sciences·G W MillerM G Caron
Jun 28, 2002·Trends in Neurosciences·Carl W Cotman, Nicole C Berchtold
Aug 31, 2002·Journal of Neural Transmission·T Obata
Nov 22, 2002·Journal of Comparative Physiology. B, Biochemical, Systemic, and Environmental Physiology·C E Cooper, P C Withers
Jan 23, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Peter TeismannSerge Przedborski
Feb 15, 2003·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Stanley J ColcombeArthur F Kramer
Apr 5, 2003·Journal of Neurochemistry·Ann D CohenMichael J Zigmond
Jun 6, 2003·The Journal of Biological Chemistry·Lea ReshefRichard W Hanson
Jul 23, 2003·CNS Drugs·Silvia MandelMoussa B H Youdim
Aug 5, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Hui-Ming GaoJau-Shyong Hong
Nov 26, 2003·Experimental Neurology·Amanda D Smith, Michael J Zigmond
Nov 26, 2003·The Journal of Cell Biology·Dermott W O'CallaghanRobert D Burgoyne
Feb 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Stanley J ColcombeSteriani Elavsky

❮ Previous
Next ❯

Citations

Aug 11, 2011·Neurotoxicity Research·Trevor Archer, Anders Fredriksson
May 1, 2012·Neurodegenerative Disease Management·Mark A HirschMohammed Sanjak
Jul 23, 2013·Neurotoxicity Research·Aderbal S AguiarRui D S Prediger
Mar 24, 2016·Journal of the Neurological Sciences·Paula Grazielle Chaves da SilvaClynton Lourenço Correa
Nov 23, 2013·Parkinsonism & Related Disorders·Michael J Zigmond, Richard J Smeyne
Jan 19, 2016·International Immunopharmacology·Lisa A RiesbergKristen M Drescher
Sep 1, 2011·Mayo Clinic Proceedings·J Eric AhlskogRonald C Petersen
Mar 29, 2011·Progress in Neurobiology·Hui-Ming Gao, Jau-Shyong Hong
Jun 12, 2010·Brain Research·Michael Zigmond, Richard J Smeyne
Mar 18, 2010·Brain Research·John A RussellTimothy Schallert
Dec 23, 2011·Parkinsonism & Related Disorders·Michael J ZigmondRichard J Smeyne
Mar 25, 2014·Dose-response : a Publication of International Hormesis Society·Rehana K Leak
Jun 19, 2013·Contemporary Clinical Trials·Charity G MooreDaniel Corcos
Aug 28, 2014·Frontiers in Cellular Neuroscience·Jun Ming Wang
Nov 18, 2015·Oxidative Medicine and Cellular Longevity·Kasthuri Bai MagalingamNagaraja Haleagrahara
Feb 1, 2017·Somatosensory & Motor Research·Andrea De Giorgio
Nov 7, 2019·Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquée, Nutrition Et Métabolisme·Zeinab RezaeeFahimeh Esfarjani
Jan 1, 2013·Brain Sciences·Tzu-Wei Lin, Yu-Min Kuo
Aug 18, 2020·Neurotoxicity Research·Zeinab RezaeeFahimeh Esfarjani
Jun 18, 2011·Expert Review of Proteomics·Jatin G Burniston, Eric P Hoffman
Jul 9, 2020·Frontiers in Aging Neuroscience·Grace F Crotty, Michael A Schwarzschild
Feb 14, 2020·International Journal of Molecular Sciences·Ewelina PalaszGrazyna Niewiadomska
Nov 23, 2017·Frontiers in Aging Neuroscience·Lijuan HouFu-Ming Zhou
Nov 19, 2019·Frontiers in Neurology·Ewelina PalaszGrazyna Niewiadomska
Dec 10, 2020·Neural Plasticity·Gabriella PolicastroGiovanna Paolone
Oct 27, 2020·Frontiers in Neuroscience·Nicholas G NorwitzMichele T Hu
Feb 22, 2021·Neuroscience Letters·Tanya SharmaThakur Gurjeet Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Atypical Parkinsonism (MDS)

Atypical Parkinsonism presents with the same signs and symptoms of Parkinson's disease, but do not respond to typical Parkionson's disease treatment with levodopa. Atypical Parkinsonism is thought to be associated with abnormal protein buildup within brain cells. Here is the latest on Atypical Parkinsonism.